Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

C. Munshi, Nikhil; D. Anderson, Larry; Shah, Nina; Madduri, Deepu; G. Berdeja, Jesús; Lonial, Sagar; Raje, Noopur; Lin, Yi; S. Siegel, David; Oriol, Albert; Moreau, Philippe; Yakoub‐Agha, Ibrahim; Delforge, Michel; Cavo, Michèle; Einsele, Hermann; Goldschmidt, Hartmut; Weisel, Katja; Rambaldi, Alessandro; Reece, Donna; Petrocca, Fabio; Massaro, Monica; N. Connarn, Jamie; M. Kaiser, Shari; Patel, Payal; Huang, Liping; Campbell, Timothy; Hege, Kristen; F. San Miguel, Jesús

doi:10.1056/nejmoa2024850

Public

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Published in New England Journal of Medicine • Feb 24, 2021

Authors:

Nikhil C. Munshi

Larry D. Anderson

Nina Shah

Abstract

BACKGROUND: Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. METHODS: CAR-positive (...

Subject

Chimeric antigen receptor

Refractory (planetary science)

Multiple myeloma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!